CHICAGO--(BUSINESS WIRE)--Chromatin Inc. announced today that it has entered into a research and commercial license agreement with Syngenta Biotechnology Inc. for Chromatin’s proprietary gene stacking technology.
CHICAGO--(BUSINESS WIRE)--Chromatin Inc. announced today that it has entered into a research and commercial license agreement with Syngenta Biotechnology Inc. for Chromatin’s proprietary gene stacking technology.